Rob Dillard

DocwireNews

Researchers assessed the Charlson comorbidity index (CCI) as a predictor of early mortality and overall survival (OS) in patients under the age of 60 with acute promyelocytic leukemia (APL). The results were presented at the 2022 American Society of Clinical Oncology Annual Meeting.Led by Prajwal Dhakal, researchers assessed 4,969 patients under the age of 60 diagnosed with APL between 2004 and 2015. The population of interest were divided into three groups based off CCI group (score of 0, 1, and &ge;2). Early mortality, defined in this study as within one-month, was assessed using multiple regression analysis, while Cox regression modeling assessed the impact of CCI on OS.According to the results, 78% of patients had a CCI of 0; 16% had CCI 1, and 6% had CCI &ge;2. The researchers observed that early mortality was 5%, 14%, and 25% for patients with CCI 0, 1, and &ge;2, respectively. Following adjustments for co-variates, the researchers found that one-month mortality was worse for patients with CCI 1 (OR=2.6; 95% CI, 2.0-3.4, P&lt;.001), and CCI &ge;2 (OR=5.3, 95% CI 3.9-7.4, P&lt;.001) compared to patients with CCI 0.The researchers concluded that the results &ldquo;indicate CCI as an important predictor of one-month mortality and OS in APL. CCI should be taken into consideration while interpreting clinical trial results.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Analyzing Mortality and Survival in Acute Promyelocytic Leukemia Using the Charlson Comorbidity Index

ASCO 2022

Researchers assessed the Charlson comorbidity index (CCI) as a predictor of early mortality and overall survival (OS) in patients under the age of 60 with acute promyelocytic ...

Analyzing Mortality and Survival in Acute Promyelocytic Leukemia Using the Charlson Comorbidity

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe